| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sonodynamic therapy (SDT) is an emerging, non-invasive treatment modality that employs ultrasound energy in conjunction with sonosensitizers to induce cytotoxicity in target tissues. A key mechanism by which SDT exerts its therapeutic effects is through the generation of reactive oxygen species (ROS). Also known as high-intensity focused ultrasound (HIFU) SDT relies on the ultrasound-triggered activation of sonosensitizers (similar in concept to photosensitizers used in photodynamic therapy). When activated by ultrasound, these compounds undergo energy transitions that lead to the production of ROS, such as singlet oxygen and free radicals. -Advantages of SDT include its non-invasive nature, deep tissue penetration of ultrasound, and the ability to target localized areas with high precision. -Challenges remain in precisely controlling ROS production and ensuring that the resulting oxidative stress is sufficient to induce cell death in tumor cells without overwhelming damage to surrounding normal tissues. Sonosensitizers: – Hematoporphyrin Derivative (HPD) and Photofrin – Protoporphyrin IX (PpIX) – Chlorin e6 (Ce6) – Phthalocyanine compounds – Titanium Dioxide (TiO2) Nanoparticles – Other metallic or semiconductor nanoparticles, sometimes functionalized or loaded with traditional sensitizer molecules (e.g., gold nanoparticles, copper-cysteamine), have been explored to enhance ROS production and improve tumor targeting. – Curcumin, derived from turmeric, has been shown in several studies to exhibit sonosensitizing properties. – Under ultrasound activation, quercetin may act as a sonosensitizer, increasing ROS generation and contributing to cancer cell apoptosis. US frequency range of 150 kHz–3 MHz, irradiation dose of 2–3 W cm−2, and the actuation duration range of 1–20 min are used for SDT research https://can-amhifu.com/ https://canadaclinicsupply.com/product/soundcare-plus-professional-dual-ultrasound-device-by-roscoe/ https://physiostore.ca/product-category/therapeutic-modalities/therapeutic-ultrasound/clinical-ultrasound-systems/ https://physiostore.ca/richmar-home-ultrasound-2000-2nd-edition/ -SDT is a pro-oxidant modality → strong antioxidants could theoretically reduce efficacy if present at high tissue levels (same logic as PDT), but this is highly protocol- and sensitizer-dependent. -Hypoxia can blunt ROS-based killing; strategies sometimes include oxygenation, microbubbles, or vascular modulation.
Time-Scale Flag (TSF): P / R / G
Sonodynamic Therapy — Common Sonosensitizer Classes
|
| Source: |
| Type: |
| Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress. Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system. cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment. While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied. Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy. Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death. Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion. Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS). "...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..." "Cancer cells have a high level of GSH compared to normal cells." "...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy." The loss of GSH is broadly known to be directly related to the apoptosis progression. |
| 1603- | Cu, | BP, | SDT, | Glutathione Depletion-Induced ROS/NO Generation for Cascade Breast Cancer Therapy and Enhanced Anti-Tumor Immune Response |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:267 Target#:137 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid